Search research articles
Contact Us
Filters
Showing results (251-260 of 261) with videos related to
Page
of 27
Sort By:
Cell Reports. Medicine
|
December 12, 2023
Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial
Rosa I Gallagher, Julia Wulfkuhle, Denise M Wolf, et al.
JAMA Ophthalmology
|
December 4, 2025
Multicenter Interspecialty Consensus on Experimental Oncology Drug-Related Ocular Adverse Event Reporting
Neel D Pasricha, Stella K Kim, Asim V Farooq, et al.
Nature Medicine
|
January 17, 2025
Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial
Alicia F C Okines, Giuseppe Curigliano, Nobumasa Mizuno, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 13, 2019
TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases
Rachel A Freedman, Rebecca S Gelman, Carey K Anders, et al.
NPJ Breast Cancer
|
August 23, 2018
Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint
Judy C Boughey, Michael D Alvarado, Rachael B Lancaster, et al.
NPJ Breast Cancer
|
January 25, 2019
Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint
Judy C Boughey, Michael D Alvarado, Rachael B Lancaster, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 2, 2021
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial
Sara M Tolaney, Nabihah Tayob, Chau Dang, et al.
NPJ Breast Cancer
|
February 17, 2022
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial
Romualdo Barroso-Sousa, Paolo Tarantino, Nabihah Tayob, et al.
Breast Cancer Research and Treatment
|
June 13, 2021
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial)
Kathryn J Ruddy, Yue Zheng, Nabihah Tayob, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 27, 2024
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT
Paolo Tarantino, Nabihah Tayob, Guillermo Villacampa, et al.
Page
of 27
Search research articles
Search
Showing results (251-260 of 261) with videos related to
Sort By:
Page
of 27
Cell Reports. Medicine
|
December 12, 2023
Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial
Rosa I Gallagher, Julia Wulfkuhle, Denise M Wolf, et al.
JAMA Ophthalmology
|
December 4, 2025
Multicenter Interspecialty Consensus on Experimental Oncology Drug-Related Ocular Adverse Event Reporting
Neel D Pasricha, Stella K Kim, Asim V Farooq, et al.
Nature Medicine
|
January 17, 2025
Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial
Alicia F C Okines, Giuseppe Curigliano, Nobumasa Mizuno, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 13, 2019
TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases
Rachel A Freedman, Rebecca S Gelman, Carey K Anders, et al.
NPJ Breast Cancer
|
August 23, 2018
Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint
Judy C Boughey, Michael D Alvarado, Rachael B Lancaster, et al.
NPJ Breast Cancer
|
January 25, 2019
Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint
Judy C Boughey, Michael D Alvarado, Rachael B Lancaster, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 2, 2021
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial
Sara M Tolaney, Nabihah Tayob, Chau Dang, et al.
NPJ Breast Cancer
|
February 17, 2022
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial
Romualdo Barroso-Sousa, Paolo Tarantino, Nabihah Tayob, et al.
Breast Cancer Research and Treatment
|
June 13, 2021
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial)
Kathryn J Ruddy, Yue Zheng, Nabihah Tayob, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 27, 2024
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT
Paolo Tarantino, Nabihah Tayob, Guillermo Villacampa, et al.
Page
of 27